Cargando…
EpCAM expression in esophageal cancer and its correlation with immunotherapy of solitomab
BACKGROUND: Recurrence of esophageal cancer (EC) after chemotherapy may mainly be explained by the existence of chemotherapy-resistant cells, and an effective drug against chemotherapy-resistant cells is highly sought. The aim of this study was to investigate the cytotoxicity of bispecific antibody...
Autores principales: | Yu, Lan, Guo, Qing-Ming, Wang, Yu, Xu, Yan, Liu, Li, Zhang, Xiao-Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107559/ https://www.ncbi.nlm.nih.gov/pubmed/34012588 http://dx.doi.org/10.21037/jtd-21-442 |
Ejemplares similares
-
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014) -
The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015) -
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
por: Ferrari, Francesca, et al.
Publicado: (2015) -
Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma
por: Armeanu-Ebinger, Sorin, et al.
Publicado: (2013) -
Expression of EpCAM in uveal melanoma
por: Odashiro, Danilo N, et al.
Publicado: (2006)